法国系统性红斑狼疮和狼疮肾炎的经济负担：一项使用法国医疗管理（SNDS）索赔数据库的全国性人群研究。

IF 3.8 3区医学 Q1 RHEUMATOLOGY

Joint Bone Spine Pub Date : 2024-11-30 DOI:10.1016/j.jbspin.2024.105827

Laurent Arnaud , Caroline Fabry-Vendrand , Remus Todea , Blandine Vidal , Juliette Cottin , Isabelle Bureau , Stéphane Bouée , Gabriel Thabut

{"title":"法国系统性红斑狼疮和狼疮肾炎的经济负担：一项使用法国医疗管理（SNDS）索赔数据库的全国性人群研究。","authors":"Laurent Arnaud , Caroline Fabry-Vendrand , Remus Todea , Blandine Vidal , Juliette Cottin , Isabelle Bureau , Stéphane Bouée , Gabriel Thabut","doi":"10.1016/j.jbspin.2024.105827","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE and LN in France, at the nationwide level.</div></div><div><h3>Methods</h3><div>Patients with SLE and LN were identified in the French nationwide health insurance database (SNDS). Prevalent SLE patients for the year 2019 were age- and sex-matched (1:1) with non-SLE controls. Direct costs (in 2019 euros) were assigned from a societal and a third-party payer perspective, using official sources.</div></div><div><h3>Results</h3><div>A total of 29,135 SLE patients, including 4357 (14.5%) with lupus nephritis, were matched to non-SLE controls. The median overall direct cost for SLE was €4795 versus €1910 for controls from a third-party payer perspective (<em>P</em>  <0.0001), for hospitalizations (+€1305 versus non-SLE controls), medications (+€872), consultations (+€343) and transportation (+€193). The overall median cost for LN was €9800 versus €3918 for SLE patients without LN, from third-party payer perspective, and €11,279 versus €4950 from a societal perspective (<em>P</em>  <0.0001). From a societal perspective the overall direct cost of SLE patients was higher (€5894) compared to non-SLE matched controls (€2601, <em>P</em>  <0.0001, for both). At a national level, the extra cost of SLE compared to non-SLE controls was M€104.9 with hospitalizations contributing to 39.6% of this extra cost.</div></div><div><h3>Conclusions</h3><div>The direct extra costs of SLE and LN are substantial in France, particularly for hospitalizations, outpatient medications, consultations, and transportations. By identifying and addressing major drivers of SLE costs, healthcare providers and policymakers can work towards more cost-effective strategies for managing SLE.</div></div>\",\"PeriodicalId\":54902,\"journal\":{\"name\":\"Joint Bone Spine\",\"volume\":\"92 3\",\"pages\":\"Article 105827\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Joint Bone Spine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297319X24001386\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297319X24001386","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：关于系统性红斑狼疮（SLE）和狼疮肾炎（LN）的经济后果的数据在欧洲很少。我们的目的是在全国范围内估计法国SLE和LN的总直接成本。方法：在法国全国健康保险数据库（SNDS）中确定SLE和LN患者。2019年流行的SLE患者与非SLE对照者年龄和性别匹配（1:1）。直接成本（以2019年欧元计）是从社会和第三方付款人的角度分配的，使用官方来源。结果：共有29135例SLE患者与非SLE对照组相匹配，其中狼疮肾炎患者4357例（14.5%）。从第三方付款人的角度来看，SLE的总直接成本中位数为4795欧元，对照组为1910欧元（结论：SLE和LN的直接额外成本在法国很大，特别是住院、门诊药物、咨询和运输费用。）通过识别和解决SLE成本的主要驱动因素，医疗保健提供者和政策制定者可以制定更具成本效益的SLE管理策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database

Objectives

Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE and LN in France, at the nationwide level.

Methods

Patients with SLE and LN were identified in the French nationwide health insurance database (SNDS). Prevalent SLE patients for the year 2019 were age- and sex-matched (1:1) with non-SLE controls. Direct costs (in 2019 euros) were assigned from a societal and a third-party payer perspective, using official sources.

Results

A total of 29,135 SLE patients, including 4357 (14.5%) with lupus nephritis, were matched to non-SLE controls. The median overall direct cost for SLE was €4795 versus €1910 for controls from a third-party payer perspective (P < 0.0001). From a societal perspective the overall direct cost of SLE patients was higher (€5894) compared to non-SLE matched controls (€2601, P < 0.0001), for hospitalizations (+€1305 versus non-SLE controls), medications (+€872), consultations (+€343) and transportation (+€193). The overall median cost for LN was €9800 versus €3918 for SLE patients without LN, from third-party payer perspective, and €11,279 versus €4950 from a societal perspective (P < 0.0001, for both). At a national level, the extra cost of SLE compared to non-SLE controls was M€104.9 with hospitalizations contributing to 39.6% of this extra cost.

Conclusions

The direct extra costs of SLE and LN are substantial in France, particularly for hospitalizations, outpatient medications, consultations, and transportations. By identifying and addressing major drivers of SLE costs, healthcare providers and policymakers can work towards more cost-effective strategies for managing SLE.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Joint Bone Spine 医学-风湿病学

CiteScore

4.50

自引率

11.90%

发文量

184

审稿时长

25 days

期刊介绍： Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology. All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.